Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus CAPEOX in first-line treatment of advanced colorectal cancer
ChiCTR2100049647Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in colorectal cancer (CRC), sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoint: progression-free survival. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100049647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049647.